Literature DB >> 28642356

Equal opportunity CAR T cells.

Rayne H Rouce1, Helen E Heslop1.   

Abstract

Mesh:

Year:  2017        PMID: 28642356      PMCID: PMC5482104          DOI: 10.1182/blood-2017-04-779983

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

Authors:  Rebecca A Gardner; Olivia Finney; Colleen Annesley; Hannah Brakke; Corinne Summers; Kasey Leger; Marie Bleakley; Christopher Brown; Stephanie Mgebroff; Karen S Kelly-Spratt; Virginia Hoglund; Catherine Lindgren; Assaf P Oron; Daniel Li; Stanley R Riddell; Julie R Park; Michael C Jensen
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

2.  Fine-tuning the CAR spacer improves T-cell potency.

Authors:  Norihiro Watanabe; Pradip Bajgain; Sujita Sukumaran; Salma Ansari; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

3.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Authors:  Yang Xu; Ming Zhang; Carlos A Ramos; April Durett; Enli Liu; Olga Dakhova; Hao Liu; Chad J Creighton; Adrian P Gee; Helen E Heslop; Cliona M Rooney; Barbara Savoldo; Gianpietro Dotti
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

4.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

5.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

6.  Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Michael Hudecek; Barbara Pender; Emily Robinson; Reed Hawkins; Colette Chaney; Sindhu Cherian; Xueyan Chen; Lorinda Soma; Brent Wood; Daniel Li; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

7.  Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.

Authors:  Nathan Singh; Jessica Perazzelli; Stephan A Grupp; David M Barrett
Journal:  Sci Transl Med       Date:  2016-01-06       Impact factor: 17.956

8.  The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Authors:  Michael Hudecek; Daniel Sommermeyer; Paula L Kosasih; Anne Silva-Benedict; Lingfeng Liu; Christoph Rader; Michael C Jensen; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-09-11       Impact factor: 11.151

Review 9.  Chimeric antigen receptors: driving immunology towards synthetic biology.

Authors:  Michel Sadelain
Journal:  Curr Opin Immunol       Date:  2016-06-30       Impact factor: 7.486

Review 10.  Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

Authors:  Stanley R Riddell; Daniel Sommermeyer; Carolina Berger; Lingfeng Steven Liu; Ashwini Balakrishnan; Alex Salter; Michael Hudecek; David G Maloney; Cameron J Turtle
Journal:  Cancer J       Date:  2014 Mar-Apr       Impact factor: 3.360

  10 in total
  2 in total

Review 1.  Chimeric antigen receptor T-cell therapies: Optimising the dose.

Authors:  Nathaniel Dasyam; Philip George; Robert Weinkove
Journal:  Br J Clin Pharmacol       Date:  2020-03-24       Impact factor: 4.335

Review 2.  Switching on the green light for chimeric antigen receptor T-cell therapy.

Authors:  Sherly Mardiana; Junyun Lai; Imran Geoffrey House; Paul Andrew Beavis; Phillip Kevin Darcy
Journal:  Clin Transl Immunology       Date:  2019-05-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.